LEADER 04322nam 2200961z- 450 001 9910576879703321 005 20231214133138.0 035 $a(CKB)5720000000008378 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84513 035 $a(EXLCZ)995720000000008378 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPresent and Future of Personalised Medicine for Endocrine Cancers 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (140 p.) 311 $a3-0365-4330-9 311 $a3-0365-4329-5 330 $aMajor technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to ?personalised cancer medicine?. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients with endocrine cancers (e.g., thyroid and adrenocortical carcinoma). In particular, each patient can be considered as a unique, individual one, with unique genetic information. The aim of this Special Issue is to offer an overview of exciting new research in the area of endocrine tumours may set the stage for an innovative personalised management and precision medicine modalities for individualised care.New affordable individual genomic analyses, as well as the opportunity to test new compounds in primary cells may allow a personalised management of patients with endocrine malignancies. This approach may improve the prediction of clinical outcome and therapeutic effectiveness, as well as help to avoid the use of ineffective drugs. However, further efforts are needed to obtain an adjustment of clinical management in patients with endocrine cancers that would rely solely or in great part on genetic information. This Special Issue includes basic, translational, and clinical papers on personalised medicine in endocrine malignancies (i.e., thyroid and adrenal), especially focusing on diagnostic and prognostic biomarkers, as well as novel drug targets or targeted treatments, including eventual clinical trials. 606 $aMedicine$2bicssc 610 $apapillary thyroid cancer 610 $aSUV PET/CT 610 $aBRAF V600E 610 $aimmune checkpoint inhibitors (ICIs) 610 $aipilimumab 610 $anivolumab 610 $aprolactinoma 610 $aCushing's disease 610 $aaggressive pituitary tumor 610 $aaggressive PitNET 610 $aaggressive pituitary adenoma 610 $apituitary carcinoma 610 $aadrenocortical cancer 610 $aadrenal adenomas 610 $aadrenal tumors 610 $ap53 610 $ap27 610 $aki-67 610 $areticulin 610 $amitotane 610 $aadjuvant treatment 610 $arecurrence 610 $arecurrence free survival 610 $atiming 610 $aintratumoral heterogeneity 610 $athyroid tumor 610 $aBRAF 610 $aRET/PTC rearrangements 610 $aRAS mutation 610 $aadrenal cortex 610 $acarcinoma 610 $aangiogenesis 610 $agene expression 610 $aosteopontin 610 $ahyaluronan synthase 1 610 $amultikinase inhibitors 610 $asorafenib 610 $alenvatinib 610 $adifferentiated thyroid cancer 610 $aradioiodine resistance 610 $apredictive marker 610 $apredictors 610 $aresponse to treatment 610 $asurvival 610 $ainformation needs and preferences 610 $afocus group interview 610 $apersonalized medicine 610 $aneuroendocrine tumours 610 $aphaeochromocytoma 610 $aparaganglioma 610 $amolecular clusters 615 7$aMedicine 700 $aRonchi$b Cristina L$4edt$01326491 702 $aAltieri$b Barbara$4edt 702 $aRonchi$b Cristina L$4oth 702 $aAltieri$b Barbara$4oth 906 $aBOOK 912 $a9910576879703321 996 $aPresent and Future of Personalised Medicine for Endocrine Cancers$93037560 997 $aUNINA